United States Biosimilars Market Opportunity & Clinical Pipeline Analysis - 100+ Biosimilars - Research and Markets
DUBLIN, July 27, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "US Biosimilars Market Opportunity & Clinical Pipeline Analysis" report to their offering.
US Biosimilars Market Opportunity & Clinical Pipeline Analysis Report Highlight:
- US Biosimilars Market Introduction
- US Biosimilars Regulatory Scenario
- Unique Features of US Biosimilars Market
- Impact of Biosimilars in US Market
- Impact of Reimbursement Policies on US Biosimilars Market
- Zarxio: First Approved Biosimilar in US
- US Biosimilar Clinical Pipeline By Company, Indication & Phase
- US Biosimilar Clinical Pipeline: 104 Biosimilars
- Marketed Biosimilars: 1 Biosimilar
Biosimilars in US has been approved after a long-time while they have been introduced in other places over a decade ago. Late entry in US market has prevented the patients from getting benefit of biosimilars. Also, spending on healthcare could have been mitigated but absence of proper regulatory framework prevented commercialization of biosimilars in US.
Number of indication under biosimilar coverage are also less, single at present, which is going to have modest effect on US market. Number of indications will increase in coming years till then US biosimilar market is expected to grow at modest rates. Slow market growth is of great concern as it is also related to cost cutting by regulators in health care spending. US biosimilars market is at nascent stage and it would take few years to become suitable niche for biosimilars.
Biologics have dominated the US market for several decades due to absence of worthy competitor in different disease segment. In coming years, this situation is expected to change as biosimilars are expected to be commercialized. Zarxio, first US biosimilar, has created lot of enthusiasm among masses but some physicians, investigators and payers have reservation against biosimilars. This scenario may cause hindrance in uptake of biosimilars in coming years.
To increase acceptance rates, biosimilar developers have to produce head-to-data confirming pharmacological efficacy. Biosimilars are also expected to have higher cost-effectiveness promoting patients to switch from biologics. In this way, biosimilar developers would be able to generate more revenues by developing positive attitude towards biosimilars.
Newly developed biosimilars in US market are expected to face hard time as regulations are not in place. Both patient and payers are expected to suffer from this issue that has to be resolved as soon as possible. Implication of new rules is expected to take some time as lots of issues have to be solved.
Naming of biosimilars and assigning of appropriate billing code is one of the fore most necessities. This situation is likely to deteriorate when monoclonal antibodies will be introduced in US market. Substitution and reimbursement will become easy if clear demarcation is made between which molecule belongs to which category. Regulators are likely to resolve these issues in coming years as they have just entered in biosimilars segment.
Key Topics Covered:
1. US Biosimilars Market Introduction
2. US Biosimilars Regulatory Scenario
3. Unique Features of US Biosimilars Market
4. Impact of Biosimilars in US Market
5. New Biosimilar Categories with High Commercialization Potential
6. Impact of Reimbursement Policies on US Biosimilars Market
7. Biobetters: Middle Ground between Biosimilars & Biologics
8. US Biosimilars Market Overview
9. Zarxio: First Approved Biosimilar in US
10. US Biosimilars Market Dynamics
11. US Biosimilars Commercialization Challenges
12. US Biosimilars Future Prospects
13. US Biosimilars Market Guidelines
14. US Biosimilar Clinical Pipeline By Company, Indication & Phase
15. Suspended & Discontued Biosimialrs in Clinical Pipeline
16. Competitive Landscape
- Amgen
- Apotex
- Boehringer Ingelheim
- Celltrion
- Coherus BioSciences
- Eli Lilly
- EPIRUS Biopharmaceuticals
- Finox Biotech
- Harvest Moon Pharmaceuticals
- Hospira
- Intas Biopharmaceuticals
- Juno Therepeutics (Opus Bio)
- Merck
- Momenta Pharmaceuticals
- Mylan
- Nora Therapeutics
- Novartis
- Oncobiologics
- Pfenex
- Pfizer
- Sandoz
- Wockhardt
For more information visit http://www.researchandmarkets.com/research/q98975/us_biosimilars
Media Contact:
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Links
http://www.researchandmarkets.com
SOURCE Research and Markets
Share this article